Quarterly ResultAug 6, 2026, 04:42 PM
Cytokinetics Q2 Net Product Revenue $25.3M; MYQORZO Launched
AI Summary
Cytokinetics reported its first net product revenue of $25.3 million for Q2 2026, following the commercial launch of MYQORZO in Q1 2026 after its FDA, EU, and China approvals in late 2025 and early 2026. The company posted a net loss of $(198.8) million for the quarter and $(404.8) million for the six months ended June 30, 2026. Despite the losses, the company significantly strengthened its financial position with $1.7 billion in cash, cash equivalents, and investments, partly due to a $760.1 million public offering and the conversion of convertible notes.
Key Highlights
- MYQORZO commercially launched in Q1 2026.
- Q2 2026 net product revenue reached $25.3 million.
- Six-month net loss was $(404.8) million.
- Six-month diluted net loss per share was $(3.17).
- Cash, cash equivalents, and investments totaled $1.7 billion.
- Raised $760.1 million from public stock offering.
- Converted $21.1 million of 2026 Notes into 2.0 million shares.
- Total stockholders' deficit improved to $(173.5) million.
Price Impact
More from CYTK